GtoPdb Ligand ID: 8251

Synonyms: CEACIDE® | hMN14
Compound class: Antibody
Comment: Labetuzumab is a humanised mouse monoclonal antibody targeting CEACAM5 (CD66e), a tumour marker that can be measured in serum.
Labetuzumab can be labelled with radioactive isotopes such as yttrium-90 and iodine-131, providing targeted radioimmumotherapy.
Labetuzumab has been used to generate an antibody-drug conjugate (ADC) called labetuzumab govitecan, in which the antibody is covalently bound to SN-38, the active metabolite of the topoisomerase inhibitor, irinotecan.
Bioactivity Comments
The preparation and use of labetuzumab appears to be covered by patent US6676924 [1] although in the absence of peptide sequences for the antibody this cannot be definitively confirmed. However, this patent does not provide a binding affinity value for the interaction between the antibody and its antigen, but the antibody'smechanism of action and primary target are substantiated by the results of biological assays.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD66e (CEACAM5) Hs Antibody Binding - - -